|Day Low/High||90.94 / 91.67|
|52 Wk Low/High||72.30 / 96.31|
- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation
- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]
Our preference is to make smaller, incremental buys as the market comes in.
Jim Cramer weighs in on why President Trump cares more about 'beating the Chinese' than the earnings reports that we receive from companies.
Let's review the charts and indicators this morning.
Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.
Jim Cramer is taking a closer look at McDonald's, Kinder Morgan, Intel, Nektar Therapeutics, L Brands, Scientific Games, and more.
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.
U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.
Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.
Cannabis' non-psychoactive derivative could disrupt the CPG (Consumer Product Group) space very soon. Watch the video for the more on the opportunities and challenges.
Alcon begins trading after its spinoff from parent company Novartis.
A look at Amgen's dispute with Novartis as well as Lam Research stock.
Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.
Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
If we can advance without China then who the heck knows where we can go with it.
Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
CBD could make coffee an around the clock craze.
Big pharma is shaping up to be a consolidating category in 2019.
One of pharma's biggest CEO's talks M&A action on the exchange.
This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
The stock's performance has been impressive in the past three months.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.